NEWS NEWS NEWS...
HOUSTON, Nov 03, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announces
the conclusion of negotiations with GSL Constructors, Ltd for the
design/build
development of a $3.8 million, 20,000 sq. ft. facility in Houston's
Westchase
District. The building will be located on a two and one-third acre site in
the
Oak Park at Westchase office park and constructed by GSL's affiliate,
Kingham
Dalton Wilson whose experience spans over 110 years and 1,000 projects.
CytoGenix plans to occupy the building in the fourth quarter of 2007.
The new facility will be the company's headquarters and provide the space
for
growth and expansion of DNA manufacturing capacity. The building will
contain
approximately 8,000 sq. ft. of state-of-the-art, GMP-qualified clean-room
space
for production of clinical-grade synDNA(TM), the company's proprietary
synthesized DNA. This area will house several production suites with
capacity to
produce 50 grams of high purity DNA daily.
Dr. Malcolm H. Skolnick, CytoGenix President and CEO, commented, "This is
a very
important step in the evolution of our company and bringing increasing
value to
our shareholders. This investment will allow us to manufacture GMP grade
material for our synDNA(TM) influenza vaccines and for our herpes
antiviral
product Simplivir(TM), as well as, supplying a growing market for clinical
grade
DNA. Once fully staffed, this facility will employ approximately 200
scientists,
technicians and other professionals. We are very happy to make this
contribution
to Houston's economic development."
Mr. Welcome Wilson, Jr., President of GSL, stated, "One of the best things
about
my job is that I get to know and work with many different kinds of
businesses.
I'm excited about the promise and the potential of the biotech industry in
Houston and about CytoGenix in particular." Brad Berry of GSL added, "We
view
our clients as partners and as such will deliver a premium product on
time."
AI
